Literature DB >> 28189459

Building smart cannabis policy from the science up.

Susan R B Weiss1, Katia D Howlett2, Ruben D Baler2.   

Abstract

Social attitudes and cultural norms around the issue of substance abuse are shifting rapidly around the world, leading to complex and unpredictable consequences. On the positive side, efforts to more intensely disseminate the scientific evidence for the many connections between chronic substance use and the emergence of measurable and discrete brain dysfunctions, has ushered in an evolving climate of acceptance and a new era of improved access to more effective interventions, at least in the United States. On the negative side, there has been a steady erosion in the public perception of the harms associated with the use of popular drugs, especially cannabis. This worrisome trend has sprouted at the convergence of several forces that have combined, more or less fortuitously, to effectively change long-standing policies away from prohibition and toward decriminalization or legalization. These forces include the outsized popularity of the cannabis plant among recreational users, the unflagging campaign by corporate lobbyists and patient advocates to mainstream its medicinal use, and the honest realization in some quarters of the deleterious impact of the drug war and its draconian cannabis laws, in particular, on society's most vulnerable populations. Updating drug policies is a desirable goal, and significant changes may indeed be warranted. However, there is a real concern when policy changes are hurriedly implemented without the required input from the medical, scientific, or policy research communities. Regardless of how well intentioned, such initiatives are bound to magnify the potential for unintended adverse consequences in the form of far ranging health and social costs. To minimize this risk, science must be front and center in this important policy debate. Here, we review the state of the science on cannabis and cannabinoid health effects, both adverse and therapeutic. We focus on the prevalence of use in different populations, the mechanisms by which cannabis exerts its effects (i.e., via the endocannabinoid system), and the double-edged potential of this system to inspire new medications, on one hand, and to cause short and long term harmful effects on the other. By providing knowledge of cannabis' broad ranging effects, we hope to enable better decision making regarding cannabis legislation and policy implementation. Published by Elsevier B.V.

Entities:  

Keywords:  Cannabis effects; Cannabis policy; Cannabis science; Medicinal cannabis

Mesh:

Substances:

Year:  2017        PMID: 28189459      PMCID: PMC5404989          DOI: 10.1016/j.drugpo.2017.01.007

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  126 in total

1.  Recent Trends in the Prevalence of Marijuana Use and Associated Disorders in the United States.

Authors:  Richard A Grucza; Arpana Agrawal; Melissa J Krauss; Patricia A Cavazos-Rehg; Laura J Bierut
Journal:  JAMA Psychiatry       Date:  2016-03       Impact factor: 21.596

2.  What can we learn from the Dutch cannabis coffeeshop system?

Authors:  Robert J MacCoun
Journal:  Addiction       Date:  2011-09-11       Impact factor: 6.526

Review 3.  Nabilone for the Management of Pain.

Authors:  Corey C Tsang; Mirella G Giudice
Journal:  Pharmacotherapy       Date:  2016-02-29       Impact factor: 4.705

4.  Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years.

Authors:  Gale A Richardson; Christopher Ryan; Jennifer Willford; Nancy L Day; Lidush Goldschmidt
Journal:  Neurotoxicol Teratol       Date:  2002 May-Jun       Impact factor: 3.763

5.  Trajectory of adolescent cannabis use on addiction vulnerability.

Authors:  Yasmin L Hurd; Michael Michaelides; Michael L Miller; Didier Jutras-Aswad
Journal:  Neuropharmacology       Date:  2013-08-14       Impact factor: 5.250

6.  Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects.

Authors:  Elizabeth J Rahn; Ganesh A Thakur; Jodi Anne T Wood; Alexander M Zvonok; Alexandros Makriyannis; Andrea G Hohmann
Journal:  Pharmacol Biochem Behav       Date:  2011-03-05       Impact factor: 3.533

Review 7.  Cannabinoids in medicine: A review of their therapeutic potential.

Authors:  Mohamed Ben Amar
Journal:  J Ethnopharmacol       Date:  2006-03-15       Impact factor: 4.360

Review 8.  Adverse health effects of marijuana use.

Authors:  Nora D Volkow; Ruben D Baler; Wilson M Compton; Susan R B Weiss
Journal:  N Engl J Med       Date:  2014-06-05       Impact factor: 91.245

9.  A controlled family study of cannabis users with and without psychosis.

Authors:  Ashley C Proal; Jerry Fleming; Juan A Galvez-Buccollini; Lynn E Delisi
Journal:  Schizophr Res       Date:  2013-12-02       Impact factor: 4.939

Review 10.  Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.

Authors:  Michelle Roche; David P Finn
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-10
View more
  7 in total

Review 1.  Cannabis use and cannabis use disorder.

Authors:  Jason P Connor; Daniel Stjepanović; Bernard Le Foll; Eva Hoch; Alan J Budney; Wayne D Hall
Journal:  Nat Rev Dis Primers       Date:  2021-02-25       Impact factor: 52.329

2.  The potential impact of cannabis legalization on the development of cannabis use disorders.

Authors:  Alan J Budney; Jacob T Borodovsky
Journal:  Prev Med       Date:  2017-06-28       Impact factor: 4.018

Review 3.  Cannabis regulatory science: risk-benefit considerations for mental disorders.

Authors:  Jacob T Borodovsky; Alan J Budney
Journal:  Int Rev Psychiatry       Date:  2018-05-29

4.  Setting the Legal Age for Access to Cannabis in Canada: Bridging Neuroscience, Policy, and Prevention.

Authors:  Rebecca J Haines-Saah; Emily K Jenkins
Journal:  Neuropsychopharmacology       Date:  2018-01       Impact factor: 7.853

5.  Is recovery from cannabis use problems different from alcohol and other drugs? Results from a national probability-based sample of the United States adult population.

Authors:  John F Kelly; M Claire Greene; Brandon G Bergman
Journal:  Int J Drug Policy       Date:  2017-12-26

Review 6.  The importance of psychology for shaping legal cannabis regulation.

Authors:  Jacob T Borodovsky; Michael J Sofis; Richard A Grucza; Alan J Budney
Journal:  Exp Clin Psychopharmacol       Date:  2020-05-21       Impact factor: 3.157

7.  Clinical trials with cannabis medicines-guidance for ethics committees, governance officers and researchers to streamline ethics applications and ensuring patient safety: considerations from the Australian experience.

Authors:  Jennifer H Martin; Courtney Hill; Anna Walsh; Daryl Efron; Kaitlyn Taylor; Michael Kennedy; Rachel Galettis; Paul Lightfoot; Julie Hanson; Helen Irving; Meera Agar; Judith Lacey
Journal:  Trials       Date:  2020-11-17       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.